Table 4 Clinical and laboratory features of pediatric SS patients
From: A single-center study of clinical features of pediatric Sjögren’s syndrome
Author (the number of patients) | Present study (n = 54) | Gong et al. [16] (n = 39) | Liu et al. [17] (n = 49) | Ramos-Casals et al. [7] (n = 158) | Legger et al. [14] (n = 23) | Kobayashi et al. [15] (n = 25) | Cimaz et al. [5] (n = 40) |
|---|---|---|---|---|---|---|---|
Data of country | China (Liaoning) | China (Shanghai) | China (Shanghai) | Multi-center | Netherlands | Japan (Hokkaido) | Multi-center |
Reported year | - | 2023 | 2023 | 2021 | 2021 | 2019 | 2003 |
Sicca symptoms | Oral 13.0% Ocular 9.3% | Oral 17.9% Ocular 10.4% | Oral 18.4% Ocular 18.4% | Oral 79.7% Ocular 70.3% | Oral 52.2% Ocular 26.1% | 16% | 35% |
ANA | 88.9% | 94.9% | 93.9% | 90.3% | 95.7% | 92% | 85.0% |
RF | 59.3% | 43.6% | 35.6% | 67.6% | 82.6% | 76% | 75.0% |
Anti-Ro/SSA antibodies | 94.4% | 100% | 85.7% | 82.7% | 82.6% | 80% | 73.6% |
Anti-La/SSB antibodies | 66.7% | 46.1% | 32.7% | 61.9% | 56.5% | 64% | |
ESSDAI domains | |||||||
Constitutional | 53.7% | 28.2% | 21.9% | 34.8% | 68% | 10% | |
Lymphadenopathy | 37.0% | 23.1% | 25.2% | 17.4% | 8% | (7.5%) | |
Glandular | 53.7% | 20.5% | 47.1% | 69.6% | 44% | 72.5% (57.5%) | |
Articular | 29.6% | 10.3% | 26.5% | 27.1% | 44% | 17.5% | |
Cutaneous | 46.3% | 35.9% | 12.3% | 8.7% | 28% | ||
Pulmonary | 1.9% | 7.7% | 5.2% | 4.3% | 0% | ||
Renal | 27.8% | 12.8% | 4.5% | 0% | 16% | (8.6%) | |
Muscular | 5.6% | 0% | 1.9% | 0% | 4% | ||
PNS | 3.7% | 2.6% | 0% | 0% | 4% | ||
CNS | 5.6% | 0% | 0.6% | 0% | 12% | (5%) | |
Haematological | 27.8% | 28.2% | 28.4% | 8.7% | 4% | ||
Biological | 75.9% | 79.5% | 54.2% | 47.8% | 96% | 53.1% | |